ArticleHistology and histopathology2020
Prognostic value of microRNA-20b expression level in patients with prostate cancer.
Article in Histology and histopathology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 7 citations in OpenAlex.
- Integrated miRNA Sequencing and Network Analysis Reveal a Molecular Continuum Between Peritumoral and Tumor Tissue in Prostate Cancer.International journal of molecular sciences · 2026Article
- Article
- The dual role of microRNA (miR)-20b in cancers: Friend or foe?Cell communication and signaling : CCS · 2023Review
- Regulation of Neuroendocrine-like Differentiation in Prostate Cancer by Non-Coding RNAs.Non-coding RNA · 2021Review
- Prognostic Value of MicroRNA-20b in Acute Myeloid Leukemia.Frontiers in oncology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 1 country.
Funding
Abstract
backgroundmiR-20b is a member of the miR-106a-363 gene cluster located in the mammalian X chromosome, the larger miR-17 family, and the miR-17-92 and miR-106b-25 gene clusters. Previous studies have indicated that miR-20b may function as oncogene or tumor suppressor in different types of cancers. The present study analyzed the association between miR-20b and clinicopathological characteristics of patients with prostate cancer.
methodsA total of 127 pairs of prostate cancer tissue samples and adjacent prostate tissue samples were collected from April 2013 to March 2018. The associations between miR-20b expression levels and clinicopathological factors were assessed using the χ2‑test. Survival was estimated using the Kaplan-Meier method, and the differences in survival according to miR-20b expression were compared using the log-rank test. Prognostic values of miR-20b expression and clinical outcomes were evaluated by Cox regression analysis.
resultsThe relative expression of miR-20b in prostate cancer tissues was significantly higher than that in adjacent noncancerous prostate tissues (P<0.001). miR-20b expression was observed to be significantly associated with Gleason score (P<0.001), lymph node metastasis (P<0.001), and TNM stage (P=0.002). The log-rank test indicated that patients with increased miR-20b expression experienced poor overall survival (P=0.037). Multivariate Cox regression analysis showed that miR-20b expression level (HR=2.181, 95% CI: 1.772-9.021, P=0.016) was an independent factor in predicting the overall survival of prostate cancer patients.
conclusionThe present study demonstrated that tissue miR-20b expression level could be a promising biomarker of prognosis in prostate cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.